Unknown

From:

Dev, Vikram J

Sent:

Thursday, January 08, 2004 11:16 AM

To:

Bassin, Lawrence G

Subject:

RE: L Bassin Drug Safety: accomplishments for performance evaluation

I think that would be appropriate

-----Original Message-

From: Bassin, Lawrence G

Sent:

Thursday, January 08, 2004 11:15 AM

To:

Dev, Vikram J

Subject:

RE: L Bassin Drug Safety: accomplishments for performance evaluation

Where would it fit on the 1 page PP slide? Right after REDACTED

Larry

----Original Message-

From:

Dev, Vikram J

Sent:

Thursday, January 08, 2004 11:08 AM

To:

Bassin, Lawrence G

Subject:

RE: L Bassin Drug Safety: accomplishments for performance evaluation

The main difference is that Seroquel is post marketing. USCD i.e. Glenn, is really interested in development projects. However, for the business and DS point of view, I think it carries equal weight in many ways, although I agree it will never reach a REDACTED but the sales are projected for REDACT by 2007 and they are on track. We have 5 surveillance staff working on Seroquel, a GDSP and TASL. If the law suit gets screwed up, AZ shares may be considerably hurt.

---Original Message--

From:

Bassin, Lawrence G

Sent:

Thursday, January 08, 2004 11:03 AM

To:

Dev, Vikram J

Subject:

RE: L Bassin Drug Safety: accomplishments for performance evaluation

Vikram

I have been thinking about Seroquel. Clearly important and clearly a lot of work and clearly an extremely important product and clearly a job well done, but is this the same type success as REDACTED rather a different type of success?

Larry

----Original Message-

From:

Dev, Vikram J

Sent:

Thursday, January 08, 2004 10:31 AM

To:

Bassin, Lawrence G

Subject:

RE: L Bassin Drug Safety: accomplishments for performance evaluation

Larry

You have very nicely summarized all the "jewels in our crown". I have a couple of comments:

- 1. In your slide under Delivering Results, you may want to add the DS contribution of Seroquel and Diabetes. This has been a huge undertaking involving weekly (or more frequently) meetings, data dredging, Reserve Press Staements, Q'&A's and slides prepared for Martin Nicklasson which he used for financial analysts. Seroquel has reached 1.5 billion \$ sales and I have feedback from the team on the great contribution of DS to make this happen and protect the compound. Ron recently received a Special Achievement Award from the US Seroquel team.
- 2. The first and third bullet points under Delivering Results are not mentioned in your table. Maybe you

did that deliberately?

I am happy to discuss, I am on a t/c until 11 AM Vikram

----Original Message-----

From: Sent:

Bassin, Lawrence G

To:

Wednesday, January 07, 2004 6:41 PM

Dev, Vikram J

Cc:

Pennington, Peggy; Steiner, Janet; Blake, Mark K

Subject:

FW: L Bassin Drug Safety: accomplishments for performance evaluation

Importance:

Vikram

This is also what I propose to use at DSMT (I think without Mark Eliason's e-mail though for this presentation). See my e-mail to Peggy and you with my request of you.

Larry

----Original Message-----

From:

Bassin, Lawrence G

Sent:

Monday, January 05, 2004 4:29 PM

To:

Gormley, Glenn J

Subject:

L Bassin Drug Safety: accomplishments for performance evaluation

Importance:

Glenn,

Below is a single slide similar to what I presented at WCLT outlining high-level Drug Safety Achievements in 2003.


<< File: WCLT Offsite - DRUG SAFETY 2003 ACCOMPLISHMENTS.ppt >> I have also included a chart that outlines US Drug Safety achievements that were part of USCD objectives.

<< File: Drug Safety USCD 2003 Support Accomplishments.doc >>

REDACTED

If you would prefer detail for any of the achievements please advise. If it is your preference, I am totally fine with keeping the review at a high level.

Larry





----Original Message-----

From:

Eliason, Mark S

Sent: To: Thursday, August 21, 2003 4:05 PM Dev, Vikram J

io: Subject:

Many Thanks....

Vikram,

REDACTED					
REDACTED					

- 2) The creation of not one, but two data listings for SAE's in the ongoing trials program for the NDA resubmission in February and June of this year. This involved a lot of programming and review by the DS team in order to meet the delivery demands of the project.
- 3) The FDA requested special monthly summary submission of ex-US spontaneous reports to the unapproved NDA, which required additional resource and coordination with Global Drug Safety and our Commercial colleagues to fullfill this request.
- 4) We also cannot forget the major DS contribution towards the Risk Management Plan which was integrated both into the NDA safety update, NDA negotiations and the preparations for the July 9, 2003 Advisory Committee meeting. The beneficial outcomes from this planning saw the formal integration of Clinical, Drug Safety and Regulatory Affairs in a team dedicated to monitoring the risk management plan on a routine basis and the sharing of information in which to make important decisions regarding outcomes from this monitoring.

REDACTED			
REDACTED			
REDACTED			
(22) (3 / 23			

Mark S. Eliason

Kind regards,

US Regulatory Director, REDACTE

Tel: 302-885-5294 Fax: 302-885-5334

A/C: Gwen Wright, 302-885-5308

Note: This e-mail message and any attachments are confidential and may be legally privileged. If you are not the intended recipient, you must not read, disseminate, or use this information. If you have received this e-

mail in error, please notify me immediately and delete it from your system.

-----Original Message-----

From:

Gormley, Glenn J

Sent: To: Monday, January 05, 2004 10:57 AM

Citabalat Kina A (UEOD)

Gilchrist, Kim A (HEOR); Jacobsen, Jack; Yuh, Lianng; Bassin, Lawrence G; Callahan-Squire, Mary P;

Felicia, Anthony S; Helaszek, Carla; Hutchinson, Howard G; Kreamer, Lori; Martin, Patrick; Sax, Rick

Subject:

accomplishments for performance evaluation

Importance: Hi

If you have not already sent me your accomplishments for 2003, can you send them as soon as you can this week. I am working on performance evaluations all week

thanks glenn